Abstract
The three deiodinase selenoenzymes are key regulators of intracellular thyroid hormone (TH) levels. The two TH-activating deiodinases (type 1 deiodinase and type 2 deiodinase (D2)) are normally expressed in follicular thyroid cells and contribute to overall TH production. During thyroid tumorigenesis, the deiodinase expression profile changes to customize intracellular TH levels to different requirements of cancer cells. Differentiated thyroid cancers overexpress the TH-inactivating type 3 deiodinase (D3), likely to reduce the TH signaling within the tumor. Strikingly, recent evidence suggests that during the late stage of thyroid tumorigenesis, D2 expression raises and this, together with a reduction in D3 expression levels, increases TH intracellular signaling in dedifferentiated thyroid cancers. These findings call into question the different functions of TH in the various stages of thyroid cancers.
Introduction
Deiodinases are three thioredoxin fold-containing selenoenzymes essential for homeostasis and control of both circulating and intracellular thyroid hormone (TH) levels. Type 1 (D1) and type 2 (D2) deiodinases convert the prohormone T4 into the active form T3 through outer ring deiodination. Their activity accounts for about 80% of the total daily T3 production in humans, while the remaining 20% of T3 and the total daily amount of T4 are produced by the thyroid gland. Type 3 deiodinase (D3), conversely, inactivates both T4 to reverse T3 (rT3), and T3 to T2 through inner ring deiodination (Bianco et al. 2002, Callebaut et al. 2003). D1 is located in the plasma membrane, whereas D2 is located in the endoplasmic reticulum, and their different subcellular location reflects their different function. In fact, the D1-derived T3 is thought to exit the cells to supply the extracellular compartment, while most of the D2-derived T3 remains in the intracellular milieu and has easier access to the nucleus to bind the T3 nuclear receptors. D3 is located in the plasma membrane and is responsible for the clearance of two-thirds of body T3 by inactivating it at both intra- and extracellular levels (Bianco et al. 2002) (Fig. 1).
Schematic design of deiodinase expression and function in the cell. The thyroid gland secretes T4 and T3 into circulation. Thyroid hormones enter the cell through thyroid hormone transporters and are subsequently metabolized based on the cell-specific deiodinase expression. D1 is located at the cell membrane and activates T4 into T3, but almost the total amount of D1-derived T3 is released in the systemic circulation. Conversely, D2 acts within the endoplasmic reticulum, close to the cell nucleus, and operates to increase the nuclear T3 concentrations on top of the serum-derived fraction of T3. D3 is also located at the cell membrane but inactivates both T4 into rT3 and T3 into T2, thus lowering the T3 nuclear concentration. D1, type 1 deiodinase; D2, type 2 deiodinase; D3, type 3 deiodinase; THT, thyroid hormone transporter.
Citation: Endocrine-Related Cancer 30, 5; 10.1530/ERC-23-0015
Schematic design of deiodinase expression and function in the cell. The thyroid gland secretes T4 and T3 into circulation. Thyroid hormones enter the cell through thyroid hormone transporters and are subsequently metabolized based on the cell-specific deiodinase expression. D1 is located at the cell membrane and activates T4 into T3, but almost the total amount of D1-derived T3 is released in the systemic circulation. Conversely, D2 acts within the endoplasmic reticulum, close to the cell nucleus, and operates to increase the nuclear T3 concentrations on top of the serum-derived fraction of T3. D3 is also located at the cell membrane but inactivates both T4 into rT3 and T3 into T2, thus lowering the T3 nuclear concentration. D1, type 1 deiodinase; D2, type 2 deiodinase; D3, type 3 deiodinase; THT, thyroid hormone transporter.
Citation: Endocrine-Related Cancer 30, 5; 10.1530/ERC-23-0015
Schematic design of deiodinase expression and function in the cell. The thyroid gland secretes T4 and T3 into circulation. Thyroid hormones enter the cell through thyroid hormone transporters and are subsequently metabolized based on the cell-specific deiodinase expression. D1 is located at the cell membrane and activates T4 into T3, but almost the total amount of D1-derived T3 is released in the systemic circulation. Conversely, D2 acts within the endoplasmic reticulum, close to the cell nucleus, and operates to increase the nuclear T3 concentrations on top of the serum-derived fraction of T3. D3 is also located at the cell membrane but inactivates both T4 into rT3 and T3 into T2, thus lowering the T3 nuclear concentration. D1, type 1 deiodinase; D2, type 2 deiodinase; D3, type 3 deiodinase; THT, thyroid hormone transporter.
Citation: Endocrine-Related Cancer 30, 5; 10.1530/ERC-23-0015
According to their specific role in TH homeostasis, deiodinases are differently expressed among human tissues. D1 is stably found in the thyroid, liver, and kidney. Conversely, D2 and D3 are found in a larger number of tissues, in many of which their expression levels change in a temporal-specific fashion to customize intracellular TH concentration in response to various stimuli, such as metabolic stress (Simonides et al. 2008, Ferdous et al. 2020), diseases (Faber et al. 1983, Mebis et al. 2007), injuries (Mancino et al. 2020, De Stefano et al. 2021), and normal physiological cell processes (Mancino et al. 2020). In such contexts, deiodinases provide finely tuned intracellular TH concentration, irrespectively from the stable circulating TH levels guaranteed by the hypothalamus–pituitary–thyroid axis. As an example, skeletal muscle finely modulates D2 and D3 levels to achieve cell-specific TH concentration during development, homeostasis, and regeneration processes. D3 is highly expressed in the early phase of myogenesis and is required for myoblasts proliferation, while D2 is expressed in the late phase of myogenesis and is required for the induction of differentiation muscle genes (Dentice et al. 2014, Ambrosio et al. 2017).
Modulation of deiodinase expression also occurs in several cancers vs their normal corresponding tissues (Nappi et al. 2021). Increased expression of D3 was found in colon cancer (Dentice et al. 2012), basal cell carcinoma (Di Girolamo et al. 2016, Miro et al. 2017), hemangiomas, gastrointestinal stromal tumors (GISTs), glioblastomas, and ovarian cancer among others (Moskovich et al. 2021) and in many human cancer-derived cell lines (Curcio et al. 2001, da-Silva et al. 2007). In these contexts, D3 upregulation might be driven by different oncogenic pathways, such as WNT-β-catenin, Sonic hedgehog, and transforming growth factor-beta (TGF-β) (Nappi et al. 2021). In D3-overexpressing tumors, the maintenance of low intracellular TH levels is necessary for tumor growth. In fact, in both cellular and mouse models, the depletion of D3 led to a reduction in cancer proliferation, and treatment with T3 was found to inhibit tumor growth both in vitro and in vivo (Dentice et al. 2012, Di Girolamo et al. 2016, Moskovich et al. 2021). However, several pieces of evidence suggest that, in some cancers, late-stage progression may require an opposite (i.e. increased) intracellular TH concentration compared to their early-stage phases. This switch from low to high intracellular T3 levels is obtained by the downregulation of D3 (first observed in colon cancer progression (Dentice et al. 2012), and a concomitant upregulation of D2 (formally demonstrated in skin tumorigenesis (Miro et al. 2019). We found that late-stage squamous cell cancer (SCC) increases D2 expression to increase intracellular T3 levels: T3 treatment increased the invasiveness of advanced SCC while, in the opposite direction, D2 depletion attenuated the metastases formation, revealing that D2-derived T3 is needed for SCC progression (Miro et al. 2019, Nappi et al. 2020).
In this review, we focus on the expression of deiodinases in thyroid neoplasias and on how their expression varies between benign lesions, differentiated cancers, and ultimately undifferentiated cancers. Deiodinase mRNA expression was the more frequently studied parameter, but we reported also activity whenever it was measured. We also discuss, in relation with data from an accompanying paper (De Stefano et al.), the molecular mechanisms that may alter the expression of deiodinases during late thyroid tumorigenesis and how changes in intracellular T3 levels may impact on the behavior of thyroid cancer cells.
Deiodinase expression in normal and hyperfunctioning thyroid tissues
Thyroid cell expresses under normal conditions both D1 and D2, but not the D3 enzyme (Galton et al. 2021). While it was long known that the thyroid expresses D1 (Berry et al. 1991, Nishikawa et al. 1998), the expression of D2 in thyroid tissue was unknown until 1996 when we discovered that DIO2 mRNA levels were 50- to 150-fold higher in human thyroid than in human placenta (Salvatore et al. 1996). The presence of D2 in the human thyroid gland was previously unknown because all the assays for D1 and D2 enzymatic activities were conducted – up to then – on rodent samples or in rat-derived cell lines (i.e. FRTL-5). It then appeared that the rodent Dio2 promoter lacks binding sites for the thyroid transcription factor-1 (TTF-1), a homeodomain protein essential for human thyroid organogenesis and maintenance of thyroid cell specificity. Unlike the rodent Dio2, the human DIO2 5′-flanking region hosts two critical DNA binding sites for TTF-1, that account for the much higher D2 expression in the human thyroid vs mouse tissue (Gereben et al. 2001).
Both D1 and D2 expression significantly increase compared to normal thyroid tissue in Graves’ disease and hyperfunctioning/toxic adenomas, two thyroid hyperproliferative diseases in which the thyroid-stimulating hormone (TSH)-receptor pathway is highly active (Salvatore et al. 1996, Laurberg et al. 2007, Ito et al. 2011). However, their upregulation is thought to follow two major different mechanisms. D1 is strongly upregulated by T3 at the transcriptional level through the binding of the T3 receptor to two distinct thyroid hormone response elements in the DIO1 gene promoter region (Toyoda et al. 1995). Differently, the increase in D2 expression mainly depends on the activation of the TSH-receptor pathway, which activates the synthesis of cyclic adenosine monophosphate (cAMP) (Field et al. 1987). The upregulation of D2 depends in turn on cAMP that binds to a cAMP response element in the DIO2 promoter region (Silva & Larsen 1983, Bartha et al. 2000). Notably, the TSH-dependent cAMP pathway also increases the mitotic activity of thyroid cells, causing goiter in Graves’ disease and cell growth of the toxic adenomas, and is paralleled by the induction of other thyroid-specific proteins such as sodium/iodide symporter and thyroglobulin (Dumont et al. 1992, Toyoda et al. 1995). Therefore, in thyroid cells that proliferate in response to TSH stimulation, D2 upregulation is corresponding to what occurs for other thyroid-specific differentiation markers.
What is the role of deiodinases in normal thyroid cells? D1 is constitutively expressed in normal thyroid follicular cells and contributes to thyroidal T3 production, as well as iodide recycling by deiodination of rT3 and sulfated iodothyronines (Maia et al. 2011). The D2 activity is closely related to TSH stimulation and is likely to provide a supplemental amount of T3 to the total thyroidal secretion in cooperation with D1 (Salvatore et al. 1996). Whether deiodinases-produced T3 contributes to the T3-bound thyroid receptor fraction in thyroid cells is presently unknown. The overall contribution to the T3 secretion by D1 and D2 is reflected by the decrease in the T4/ T3 molar ratio from 15:1 in thyroglobulin-bound hormones to 11:1 in the thyroid output, which is observed in Graves’ disease and hyperfunctioning thyroid nodules (Salvatore et al. 2022).
Non-functioning follicular thyroid adenomas and carcinomas have a similar deiodinase expression profile
Polyclonal hyperplasia is commonly found within nontoxic multinodular goiters (MNG) and is the result of the non-clonal proliferation of multiple cells (Kopp et al. 1994). Analyses of deiodinase expression in MNG of patients with normal serum TSH levels indicate that D1 and D2 show similar expression and activity in MNG when compared to normal thyroid tissue (Salvatore et al. 1996, Pereira et al. 2012). Conversely, follicular thyroid adenomas (FTA) are monoclonal and arise from the proliferation of a single cell after the acquisition of a growth advantage due to the accumulation of genetic mutations (Kondo et al. 2006). Non-functioning FTA may lose the ability to incorporate iodide, in which case they appear as ‘cold nodules’ at thyroid scintigraphy, and this is related to a decreased expression of sodium iodine symporter (NIS). In such non-functioning FTA, the expression of the other thyroid functional proteins such as thyroid peroxidase (TPO), thyroglobulin, and TSH receptor is maintained (Russo et al. 2001). Few studies of small-sized groups of non-functioning FTA showed that both D1 and D2 gene expression and activity are similar (Arnaldi et al. 2005) or increased (de Souza Meyer et al. 2005, Pereira et al. 2012) when compared to normal thyroid tissue, with similar TSH levels.
Both FTA and follicular thyroid cancer (FTC) are frequently driven by point mutations in RAS genes or PPARG fusion genes and share common cytological features and histological architecture (Marques et al. 2002, Nikiforova et al. 2003, Kondo et al. 2006). However, FTCs are invasive lesions that invade the tumor capsule, the thyroid gland capsule, and/or tumor vessels (D'Avanzo et al. 2004). Compared to normal thyroid tissue, FTC may show various degrees of D1 expression and similar levels of D2 expression (Arnaldi et al. 2005, de Souza Meyer et al. 2005). This is consistent with the low MAPK-signaling associated with RAS and RAS-like mutations and with the maintained expression of other markers of thyroid differentiation. Initial studies of D1 in human specimens of FTC reported normal to lower activity and expression of the 27-kDa substrate-binding subunit of D1, which was stimulated in two FTC cell lines by retinoic acid (Köhrle et al. 1993, Schreck et al. 1994). In a subsequent series of 11 FTA and 15 FTC, there were no significant differences in the expression level of D1 and D2 compared to surrounding normal thyroid tissue in any of these tumors (Arnaldi et al. 2005). Vice versa, D1 expression was significantly upregulated in a smaller series of seven FTA and six FTC compared to healthy thyroid tissue (de Souza Meyer et al. 2005). Increased DIO1 mRNA levels were paralleled by increased D1 activity in FTA and in samples of FTC metastases. This study also reported a D2 expression in FTC similar to normal thyroid tissue, but D2 activity was consistently higher in FTC than in surrounding tissue.
The presence of T4-to-T3 converting deiodinases in FTC was also described in patients with large tumor masses in which the amount of D1 and/ or D2 was so elevated (due to the elevated tumor burden) that it led to decreased serum T4/T3 ratio. Higher expression levels of D1 and D2 than in normal thyroid tissue were found in at least four FTC from patients with increased serum T3 levels in three different studies (Kim et al. 2003, Takano et al. 2006, Miyauchi et al. 2008). A general observation in patients with hyperfunctioning FTC is a reduction in serum T4 and an increase in serum T3 concentrations that depend on an increased T4-to-T3 conversion. In most of these hyperfunctioning FTC, an activating mutation of the TSH receptor gene or of the Gsα gene was found (Brunetti et al. 2000).
Papillary thyroid carcinoma expresses D3 and downregulates D1 and D2
Papillary thyroid cancers (PTCs) are driven in about 50–60% of cases by the BRAFV600E mutation, while 5–20% of cases show fusion genes such as RET/PTC, PAX8-PPARG, and NTRK1/3 rearrangements, and 10–15% show RAS mutations (Cancer Genome Atlas Research 2014, Fagin & Wells 2016). These oncogenic driver mutations are mutually exclusive and lead to significantly different signaling consequences. PTC harboring RAS and RAS-like mutations (such as PAX8-PPARG and BRAFK601E) show follicular architecture and are defined as follicular variant-PTC (FV-PTC). They retain most of the functional properties of normal thyroid cells and have a deiodinase expression profile similar to FTA and FTC (Arnaldi et al. 2005). Differently, PTC driven by BRAFV600E and BRAFV600E-like mutations (such as RET/PTC and BRAF fusion genes) show a higher MAPK-signaling activity compared to RAS-driven tumors. As a consequence, they lack expression of thyroid differentiation genes that include those involved in iodide uptake and metabolism, and the thyroid deiodinases D1 and D2 (Cancer Genome Atlas Research 2014).
The first observation that D2 expression and activity are decreased in six PTCs came from a study by Murakami et al. (2001). In a subsequent analysis, Ambroziak et al. (2005) found a robust decrease in DIO2 mRNA in 8 out of 10 PTC samples and a concomitant downregulation of DIO1 mRNA levels. Similarly, Arnaldi et al. (2005) reported a significant downregulation in both DIO1 and DIO2 in a series of 26 PTC compared to normal thyroid tissue. Further insights came from a series of 14 PTC (de Souza Meyer et al. 2005) that showed a strong reduction of DIO1 expression in all PTC samples compared to healthy thyroid tissue and a reduction in D1 enzymatic activity that significantly correlated with the DIO1 mRNA reduction. The decline in both the T3-producing D1 and D2 in PTC can be simply the results from a reduction of D1 and D2 expression related to oncogenic transformation. However, two studies found that human PTCs significantly increase their D3 expression levels (Romitti et al. 2012, Romitti et al. 2016) and activity (Romitti et al. 2016), suggesting that PTC tumorigenesis may benefit from low intracellular TH levels. In a study of 26 PTC samples (Romitti et al. 2012), the D3 expression levels were increased compared to adjacent normal tissue – in which D3 was normally absent (Table 1). Furthermore, the BRAFV600E-mutated PTC samples showed significantly higher D3 expression and activity than BRAF-wild type controls.
Summary of deiodinase changes in human thyroid malignancies.
| Type of cancer | D1 | D2 | D3 | Author/year |
|---|---|---|---|---|
| Follicular thyroid cancer | N/A | Increased | N/A | Kim et al. (2003) |
| Follicular thyroid cancer | Increased | Increased | N/A | Arnaldi et al. (2005) |
| Follicular thyroid cancer | Increased | Increased | N/A | de Souza Meyer et al. (2005) |
| Follicular thyroid cancer | Increased | Increased | N/A | Takano et al. (2006) |
| Follicular thyroid cancer | Increased | Increased | N/A | Miyauchi et al. (2008) |
| Papillary thyroid cancer | N/A | Decreased | N/A | Murakami et al. (2001) |
| Papillary thyroid cancer | Decreased | Decreased | N/A | Arnaldi et al. (2005) |
| Papillary thyroid cancer | Decreased | Decreased | N/A | Ambroziak et al. (2005) |
| Papillary thyroid cancer | Decreased | N/A | N/A | de Souza Meyer et al. (2005) |
| Papillary thyroid cancer | N/A | N/A | Increased | Romitti et al. (2012, 2016) |
| Anaplastic thyroid cancer | Decreased | Increased | Decreased | De Stefano et al., accompanying manuscript |
The deiodinase expression profile was also studied in cell line models of PTCs, and a similar profile was observed when compared to the corresponding human tumors. Indeed, DIO1 and DIO2 were found significantly downregulated in the PTC cell line NPA-87 compared to normal thyroid cells (Arnaldi et al. 2005). Moreover, the D3 expression and activity were significantly increased in a PTC cell line harboring the BRAFV600E mutation (K1 cells), compared to normal thyroid cells. In K1 cells, reduction in DIO3 mRNA by RNA interference caused a reduction in cyclin D1 levels, a cyclin involved in the control of the cell cycle (Romitti et al. 2016). The molecular mechanisms behind D3 induction in PTC are still unknown. However, it has been demonstrated that mutated BRAFV600E increases the TGFB1 expression (Riesco-Eizaguirre et al. 2009, Knauf et al. 2011) and that in different cell contexts, TGF-β induces the transcription of human D3 through a Smad-dependent pathway (Azouzi et al. 2017).
Overall, these data support the idea that a low intracellular TH signaling is functional for PTC growth or maintenance. The low TH signaling is achieved not only by abolishing intra-thyroidal T3 production (low D1 and D2 activities) but also by a pro-active tool which consists in D3 activation, thus preserving PTC cells from the TH entry from blood circulation. The molecular signature controlled by T3 in PTC cells is still unknown.
Anaplastic thyroid cancer expresses D2
Anaplastic thyroid cancer (ATC) represents the end result of the dedifferentiation of follicular cell-derived thyroid cancers (Fagin & Wells 2016) (Fig. 2). This is a rare cancer (<1% of all thyroid cancers), but it is an aggressive and rapidly progressive tumor that accounts for one-third of all deaths from thyroid cancer (Landa et al. 2016). The accumulation of a high burden of mutations plays a key role in the progression of differentiated thyroid cancer to the undifferentiated state and determines the loss of thyroid-specific proteins, such as thyroglobulin, TPO, and TSH-receptor, and the two thyroid-specific transcription factors TTF-1 and PAX-8 (Fabbro et al. 1994, Nikiforov 2004). Initial characterization of deiodinase expression in ATC showed that D1 was undetectable in both human ATC samples and cell models (namely, HTh 74 and C 643) (Schreck et al. 1994), a finding that is in agreement with D1 as a thyroid differentiation marker. However, a subsequent study of both D1 and D2 activity in a single sample of human ATC showed a significant increase of T4-to-T3 conversion in cancer tissue as compared to surrounding normal thyroid tissue for both enzymatic assays (de Souza Meyer et al. 2005). In addition, immunohistochemistry in one human ATC sample showed no D3 staining (Romitti et al. 2012) suggesting a change in the deiodinase expression profile as compared to PTC.
Schematic representation of deiodinase expression and thyroid hormone levels in thyroid tumorigenesis. The diagram shows the deiodinase expression and their variations along the major steps of thyroid tumorigenesis. ATC, anaplastic thyroid cancer; D1, type 1 deiodinase; D2, type 2 deiodinase; D3, type 3 deiodinase; FTC, follicular thyroid cancer; PTC, papillary thyroid cancer.
Citation: Endocrine-Related Cancer 30, 5; 10.1530/ERC-23-0015
Schematic representation of deiodinase expression and thyroid hormone levels in thyroid tumorigenesis. The diagram shows the deiodinase expression and their variations along the major steps of thyroid tumorigenesis. ATC, anaplastic thyroid cancer; D1, type 1 deiodinase; D2, type 2 deiodinase; D3, type 3 deiodinase; FTC, follicular thyroid cancer; PTC, papillary thyroid cancer.
Citation: Endocrine-Related Cancer 30, 5; 10.1530/ERC-23-0015
Schematic representation of deiodinase expression and thyroid hormone levels in thyroid tumorigenesis. The diagram shows the deiodinase expression and their variations along the major steps of thyroid tumorigenesis. ATC, anaplastic thyroid cancer; D1, type 1 deiodinase; D2, type 2 deiodinase; D3, type 3 deiodinase; FTC, follicular thyroid cancer; PTC, papillary thyroid cancer.
Citation: Endocrine-Related Cancer 30, 5; 10.1530/ERC-23-0015
New insights on deiodinase expression in ATC came from data derived from two studies on ATC tumorigenesis. In a series of 20 human ATC (Landa et al. 2016), the 16-gene thyroid differentiation score derived from the TCGA study (Cancer Genome Atlas Research 2014) (that includes D1 and D2 and reflects the differentiation state of a given thyroid tumor) was used to analyze the effect of the ATC driver mutations on thyroid cancer cell metabolism and specification compared to a group of 9 PTCs. Through the analysis of the published dataset, we observed much lower levels of D1 mRNA in ATC compared to PTC but, surprisingly, increased levels of D2 expression, that were similar to levels found in normal thyroid tissue (Fig. 3). The marked downregulation of D1, whose activity is unrelated to the nuclear fraction of the TH receptor-bound T3, paralleled by enhanced D2 expression, supports the concept that D2 re-expression in ATC does not likely reflect the primary thyroid function to release T3, but rather the requirement to increase the intracellular nuclear T3 concentration in ATC cells. This concept is supported by data on ATC cells obtained upon D2 depletion, which indicate a requirement of D2 action in these cells to survive and maintain their cancer phenotypes (De Stefano et al. accompanying manuscript). The second clue on the potential role of D2 in ATC tumorigenesis came from an ATAC-seq analysis performed in ATC from mice carrying BRAFV600E mutation and SWI/SNF loss (Saqcena et al. 2021). This model indicated that the loss of three different subunits of SWI/SNF chromatin remodeling complexes impairs the expression of thyroid differentiation genes, thereby promoting the progression of PTC to an undifferentiated state. In particular, the loss of the SMARCB1 subunit leads to anaplastic transformation in about 90% of BRAFV600E -mutated PTCs. Strikingly, the BRAFV600E/SMARCB1-mutated ATC showed similar levels of chromatin accessibility at DIO2 locus than wildtype controls, but impaired accessibility at DIO1 consistent with the loss of expression of other thyroid differentiation genes, with the exception of DIO2.
Array analysis of type 1 deiodinase gene (DIO1) and type 2 deiodinase gene (DIO2) expression in human thyroid cancer from the series GSE3467 and GSE76039 (Landa et al. 2016) analyzed using Expression Console. *P < 0.05; **P < 0.01; ***P < 0.001.
Citation: Endocrine-Related Cancer 30, 5; 10.1530/ERC-23-0015
Array analysis of type 1 deiodinase gene (DIO1) and type 2 deiodinase gene (DIO2) expression in human thyroid cancer from the series GSE3467 and GSE76039 (Landa et al. 2016) analyzed using Expression Console. *P < 0.05; **P < 0.01; ***P < 0.001.
Citation: Endocrine-Related Cancer 30, 5; 10.1530/ERC-23-0015
Array analysis of type 1 deiodinase gene (DIO1) and type 2 deiodinase gene (DIO2) expression in human thyroid cancer from the series GSE3467 and GSE76039 (Landa et al. 2016) analyzed using Expression Console. *P < 0.05; **P < 0.01; ***P < 0.001.
Citation: Endocrine-Related Cancer 30, 5; 10.1530/ERC-23-0015
In line with these results, in a recent study from our group (De Stefano et al. accompanying manuscript), we found that DIO2 is highly expressed in two ATC cell lines (i.e. 8505c and KMH2) compared to PTC cells lines (i.e. K1 and TPC-1), while DIO1 is strongly downregulated in both cell models compared to normal thyroid cells. We also found that ATC cells upregulate the expression of thyroid hormone nuclear receptor (THR) α while suppress the THRβ (which is the major isoform expressed in normal thyroid), possibly suggesting that the D2-derived T3 in ATC acts on a different subset of target genes through the expression of a different THR isoform. Most importantly, our study showed that D2-blocking in ATC induced cell senescence and significantly blunted their invasive potential.
Overall, D3 upregulation in PTC suggests that low intracellular T3 level is paralleled by a low proliferation rate and relatively slow tumor growth, while the D2 upregulation in ATC (i.e. higher intracellular T3) is needed in rapidly growing tumors. However, in PTC cells, we observed that an enhanced intracellular T3 is accompanied by senescence (unpublished data) suggesting that it is not the absolute intracellular T3 concentration that promotes/hampers tumor proliferation, rather its adjustment is cell-context dependent and represents a cell-specific requirement in thyroid cancer cells. The pathological meaning of the higher intracellular T3 requirements in ATC compared to PTC still need to be investigated. Among multiple mechanisms, the increase in D2-derived T3 in ATC may support the increased energy consumption consequent to its highly proliferative state. In such a situation, cancer cells enhance aerobic glycolysis as a source of ATP for the increased energy request (Bao et al. 2021). Notably, T3 increases the expression of glycolytic genes (such as aldolase A, enolase, pyruvate kinase M2, and lactate dehydrogenase A) (Miro et al. 2021), as well as the glucose transporter genes GLUT1, 3, and 4 (Casla et al. 1990).
The hypothesis that D2 is associated with cancer dedifferentiation in thyroid tumorigenesis has to be confirmed, but it would be in line with observations in other cancer contexts. In skin squamous cell carcinoma (Miro et al. 2019) and colon cancer (Dentice et al. 2012), we showed that D3 is dramatically downregulated at later phases of tumorigenesis and that the expression of D2 is upregulated in high-grade squamous cell carcinoma. High D2 expression levels have also been found in other advanced cancer cells vs their respective normal cells, such as rhabdomyosarcoma (RMS-13) (da-Silva et al. 2007) and mesothelioma cell lines (MSTO-211H) (Curcio et al. 2001). The reciprocal opposite changes in D2 and D3 expression increase the intracellular concentration of T3, but the role of the T3 signaling in cancer progression is largely unknown. The identification of the ZEB-1 pathway as positively induced by T3 seems to indicate that T3 is required for the fully advanced and metastatic properties of cancer cells (Miro et al. 2019).
What are the molecular drivers of D2 in ATCs? We do not know the answer yet, neither whether D2 upregulation only occurs in the epithelial ATC cells or also in the stromal/immune cell components, which are particularly relevant in the bulk of ATC (Landa et al. 2016). However, in our aforementioned study (De Stefano et al. accompanying manuscript), we found that a mutant p53 transfected in PTC cells potently induces DIO2 expression. Given that mutated p53 is a major driver of PTC to ATC transition, this observation helps to understand the expression of D2 in ATC with mutated p53. Supporting this hypothesis, we conducted an in silico analysis of deiodinase expression of murine BRAFV600E -mutated PTC and BRAFV600E /TP53 ATC from arrays derived from a recent study of Knauf et al. (Knauf et al. 2018) (Fig. 4). Strikingly, we found that D2 expression is upregulated in ATC compared with PTC, wherein it is even higher than in normal thyroid tissue. Conversely, D1 expression in ATC is similarly absent as in PTC, that is, significantly lower than in normal thyroid tissue. These results are consistent with the expression data in human ATC and prompt the need for further investigations of the potential role of D2 in ATC tumorigenesis.
Array analysis of type 1 deiodinase gene (Dio1) and type 2 deiodinase gene (Dio2) expression in a mouse model of BRAFV600E -mutated PTC and BRAFV600E/TP53 ATC (from (Knauf et al. 2018). Dataset from GSE118022 was analyzed using GEO2R. *P < 0.05; **P < 0.01; ***P < 0.001.
Citation: Endocrine-Related Cancer 30, 5; 10.1530/ERC-23-0015
Array analysis of type 1 deiodinase gene (Dio1) and type 2 deiodinase gene (Dio2) expression in a mouse model of BRAFV600E -mutated PTC and BRAFV600E/TP53 ATC (from (Knauf et al. 2018). Dataset from GSE118022 was analyzed using GEO2R. *P < 0.05; **P < 0.01; ***P < 0.001.
Citation: Endocrine-Related Cancer 30, 5; 10.1530/ERC-23-0015
Array analysis of type 1 deiodinase gene (Dio1) and type 2 deiodinase gene (Dio2) expression in a mouse model of BRAFV600E -mutated PTC and BRAFV600E/TP53 ATC (from (Knauf et al. 2018). Dataset from GSE118022 was analyzed using GEO2R. *P < 0.05; **P < 0.01; ***P < 0.001.
Citation: Endocrine-Related Cancer 30, 5; 10.1530/ERC-23-0015
Conclusions
The presence of a specific modulation in the expression of deiodinases during thyroid tumorigenesis suggests that not only changes in TH metabolism occur early in thyroid tumorigenesis but also that initial and late-phase thyroid cancers require different intracellular TH concentrations. Strictly depending on tumor stage, the TH signaling seems to be able to either impair (in differentiated cancer) or promote (in undifferentiated) the tumor growth. The opposite variations in intracellular TH signaling between low- and high-grade thyroid cancers predicted from these divergent deiodinase expressions shed new light on the role of TH in tumor progression. Far from being only related to lack of thyroid differentiation, the significant D2 expression in ATC suggests that the elevated TH signaling is active in high-grade thyroid cancers. This represents a novel and neglected aspect of thyroid tumorigenesis that raises important questions on the role of TH action in tumor progression and requires deeper studies. The accumulating knowledge in TH signaling in thyroid cancer will possibly allow to identify selected actors of TH signaling as new potential stage-specific target in thyroid cancer treatment.
Declaration of interest
All authors declare no competing interests.
Funding
This study was supported by AIRC Individual Grant to DS (IG 2022, Project Number 27729) and by National Center for Gene Therapy and Drugs based on RNA Technology MUR-CN3 CUP E63C22000940007 to DS.
Author contribution statement
All authors contributed to the manuscript and approved its final version.
References
Ambrosio R, De Stefano MA, Di Girolamo D & & Salvatore D 2017 Thyroid hormone signaling and deiodinase actions in muscle stem/progenitor cells. Molecular and Cellular Endocrinology 459 79–83. (https://doi.org/10.1016/j.mce.2017.06.014)
Ambroziak M, Pachucki J, Stachlewska-Nasfeter E, Nauman J & & Nauman A 2005 Disturbed expression of type 1 and type 2 iodothyronine deiodinase as well as titf1/nkx2-1 and pax-8 transcription factor genes in papillary thyroid cancer. Thyroid 15 1137–1146. (https://doi.org/10.1089/thy.2005.15.1137)
Arnaldi LAT, Borra RC, Maciel RMB & & Cerutti JM 2005 Gene expression profiles reveal that DCN, DIO1, and DIO2 are underexpressed in benign and malignant thyroid tumors. Thyroid 15 210–221. (https://doi.org/10.1089/thy.2005.15.210)
Azouzi N, Cailloux J, Cazarin JM, Knauf JA, Cracchiolo J, Al Ghuzlan A, Hartl D, Polak M, Carre A, El Mzibri M, et al.2017 NADPH oxidase NOX4 is a critical mediator of BRAF(V600E)-induced downregulation of the sodium/iodide symporter in papillary thyroid carcinomas. Antioxidants and Redox Signaling 26 864–877. (https://doi.org/10.1089/ars.2015.6616)
Bao L, Xu T, Lu X, Huang P, Pan Z & & Ge M 2021 Metabolic reprogramming of thyroid cancer cells and crosstalk in their microenvironment. Frontiers in Oncology 11 773028. (https://doi.org/10.3389/fonc.2021.773028)
Bartha T, Kim SW, Salvatore D, Gereben B, Tu HM, Harney JW, Rudas P & & Larsen PR 2000 Characterization of the 5'-flanking and 5'-untranslated regions of the cyclic adenosine 3',5'-monophosphate-responsive human Type 2 iodothyronine deiodinase Gene1. Endocrinology 141 229–237. (https://doi.org/10.1210/endo.141.1.7282)
Berry MJ, Banu L & & Larsen PR 1991 Type I iodothyronine deiodinase is a selenocysteine-containing enzyme. Nature 349 438–440. (https://doi.org/10.1038/349438a0)
Bianco AC, Salvatore D, Gereben B, Berry MJ & & Larsen PR 2002 Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocrine Reviews 23 38–89. (https://doi.org/10.1210/edrv.23.1.0455)
Brunetti A, Chiefari E, Filetti S & & Russo D 2000 The 3',5'-cyclic adenosine monophosphate response element binding protein (CREB) is functionally reduced in human toxic thyroid adenomas. Endocrinology 141 722–730. (https://doi.org/10.1210/endo.141.2.7331)
Callebaut I, Curcio-Morelli C, Mornon JP, Gereben B, Buettner C, Huang S, Castro B, Fonseca TL, Harney JW, Larsen PR, et al.2003 The iodothyronine selenodeiodinases are thioredoxin-fold family proteins containing a glycoside hydrolase clan GH-A-like structure. Journal of Biological Chemistry 278 36887–36896. (https://doi.org/10.1074/jbc.M305725200)
Cancer Genome Atlas Research. 2014. Integrated genomic characterization of papillary thyroid carcinoma. Cell 159 676–690.
Casla A, Rovira A, Wells JA & & Dohm GL 1990 Increased glucose transporter (GLUT4) protein expression in hyperthyroidism. Biochemical and Biophysical Research Communications 171 182–188. (https://doi.org/10.1016/0006-291X(9091374-2)
Curcio C, Baqui MMA, Salvatore D, Rihn BH, Mohr S, Harney JW, Larsen PR & & Bianco AC 2001 The human type 2 iodothyronine deiodinase is a selenoprotein highly expressed in a mesothelioma cell line. Journal of Biological Chemistry 276 30183–30187. (https://doi.org/10.1074/jbc.C100325200)
da-Silva WS, Harney JW, Kim BW, Li J, Bianco SDC, Crescenzi A, Christoffolete MA, Huang SA & & Bianco AC 2007 The small polyphenolic molecule kaempferol increases cellular energy expenditure and thyroid hormone activation. Diabetes 56 767–776. (https://doi.org/10.2337/db06-1488)
D'Avanzo A, Treseler P, Ituarte PHG, Wong M, Streja L, Greenspan FS, Siperstein AE, Duh QY & & Clark OH 2004 Follicular thyroid carcinoma: histology and prognosis. Cancer 100 1123–1129. (https://doi.org/10.1002/cncr.20081)
de Souza Meyer EL, Dora JM, Wagner MS & & Maia AL 2005 Decreased type 1 iodothyronine deiodinase expression might be an early and discrete event in thyroid cell dedifferentation towards papillary carcinoma. Clinical Endocrinology 62 672–678. (https://doi.org/10.1111/j.1365-2265.2005.02277.x)
De Stefano MA, Ambrosio R, Porcelli T, Orlandino G, Salvatore D & & Luongo C 2021 Thyroid hormone action in muscle atrophy. Metabolites 11 730. (https://doi.org/10.3390/metabo11110730)
Dentice M, Ambrosio R, Damiano V, Sibilio A, Luongo C, Guardiola O, Yennek S, Zordan P, Minchiotti G, Colao A, et al.2014 Intracellular inactivation of thyroid hormone is a survival mechanism for muscle stem cell proliferation and lineage progression. Cell Metabolism 20 1038–1048. (https://doi.org/10.1016/j.cmet.2014.10.009)
Dentice M, Luongo C, Ambrosio R, Sibilio A, Casillo A, Iaccarino A, Troncone G, Fenzi G, Larsen PR & & Salvatore D 2012 Beta-catenin regulates deiodinase levels and thyroid hormone signaling in colon cancer cells. Gastroenterology 143 1037–1047. (https://doi.org/10.1053/j.gastro.2012.06.042)
Di Girolamo D, Ambrosio R, De Stefano MA, Mancino G, Porcelli T, Luongo C, Di Cicco E, Scalia G, Vecchio LD, Colao A, et al.2016 Reciprocal interplay between thyroid hormone and microRNA-21 regulates hedgehog pathway-driven skin tumorigenesis. Journal of Clinical Investigation 126 2308–2320. (https://doi.org/10.1172/JCI84465)
Dumont JE, Lamy F, Roger P & & Maenhaut C 1992 Physiological and pathological regulation of thyroid cell proliferation and differentiation by thyrotropin and other factors. Physiological Reviews 72 667–697. (https://doi.org/10.1152/physrev.1992.72.3.667)
Fabbro D, Di Loreto C, Beltrami CA, Belfiore A, Di Lauro R & & Damante G 1994 Expression of thyroid-specific transcription factors TTF-1 and PAX-8 in human thyroid neoplasms. Cancer Research 54 4744–4749.
Faber J, Heaf J, Kirkegaard C, Lumholtz IB, Siersbaek-Nielsen K, Kolendorf K & & Friis T 1983 Simultaneous turnover studies of thyroxine, 3,5,3' and 3,3',5'-triiodothyronine, 3,5-, 3,3'-, and 3',5'- diiodothyronine, and 3'-monoiodothyronine in chronic renal failure. Journal of Clinical Endocrinology and Metabolism 56 211–217. (https://doi.org/10.1210/jcem-56-2-211)
Fagin JA & & Wells SA 2016 Biologic and clinical perspectives on thyroid cancer. New England Journal of Medicine 375 1054–1067. (https://doi.org/10.1056/NEJMra1501993)
Ferdous A, Wang ZV, Luo Y, Li DL, Luo X, Schiattarella GG, Altamirano F, May HI, Battiprolu PK, Nguyen A, et al.2020 FoxO1-Dio2 signaling axis governs cardiomyocyte thyroid hormone metabolism and hypertrophic growth. Nature Communications 11 2551. (https://doi.org/10.1038/s41467-020-16345-y)
Field JB, Ealey PA, Marshall NJ & & Cockcroft S 1987 Thyroid-stimulating hormone stimulates increases in inositol phosphates as well as cyclic AMP in the FRTL-5 rat thyroid cell line. Biochemical Journal 247 519–524. (https://doi.org/10.1042/bj2470519)
Galton VA, Larsen PR & & Berry MJ 2021 The deiodinases: their identification and cloning of their genes. Endocrinology 162 bqab005. (https://doi.org/10.1210/endocr/bqab005)
Gereben B, Salvatore D, Harney JW, Tu HM & & Larsen PR 2001 The human, but not rat, dio2 gene is stimulated by thyroid transcription factor-1 (TTF-1). Molecular Endocrinology 15 112–124. (https://doi.org/10.1210/mend.15.1.0579)
Ito M, Toyoda N, Nomura E, Takamura Y, Amino N, Iwasaka T, Takamatsu J, Miyauchi A & & Nishikawa M 2011 Type 1 and type 2 iodothyronine deiodinases in the thyroid gland of patients with 3,5,3'-triiodothyronine-predominant Graves' disease. European Journal of Endocrinology 164 95–100. (https://doi.org/10.1530/EJE-10-0736)
Kim BW, Daniels GH, Harrison BJ, Price A, Harney JW, Larsen PR & & Weetman AP 2003 Overexpression of type 2 iodothyronine deiodinase in follicular carcinoma as a cause of low circulating free thyroxine levels. Journal of Clinical Endocrinology and Metabolism 88 594–598. (https://doi.org/10.1210/jc.2002-020921)
Knauf JA, Luckett KA, Chen KY, Voza F, Socci ND, Ghossein R & & Fagin JA 2018 Hgf/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers. Journal of Clinical Investigation 128 4086–4097. (https://doi.org/10.1172/JCI120966)
Knauf JA, Sartor MA, Medvedovic M, Lundsmith E, Ryder M, Salzano M, Nikiforov YE, Giordano TJ, Ghossein RA & & Fagin JA 2011 Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFbeta signaling. Oncogene 30 3153–3162. (https://doi.org/10.1038/onc.2011.44)
Köhrle J, Oertel M, Hoang-Vu C, Schnieders F & & Brabant GJECE 1993 Type I 5’-deiodinase—a marker for differentiated thyroid carcinoma? Experimental and Clinical Endocrinology & Diabetes 101 60–72.
Kondo T, Ezzat S & & Asa SL 2006 Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nature Reviews Cancer 6 292–306. (https://doi.org/10.1038/nrc1836)
Kopp P, Kimura ET, Aeschimann S, Oestreicher M, Tobler A, Fey MF & & Studer H 1994 Polyclonal and monoclonal thyroid nodules coexist within human multinodular goiters. Journal of Clinical Endocrinology and Metabolism 79 134–139. (https://doi.org/10.1210/jcem.79.1.7517946)
Landa I, Ibrahimpasic T, Boucai L, Sinha R, Knauf JA, Shah RH, Dogan S, Ricarte-Filho JC, Krishnamoorthy GP, Xu B, et al.2016 Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. Journal of Clinical Investigation 126 1052–1066. (https://doi.org/10.1172/JCI85271)
Laurberg P, Vestergaard H, Nielsen S, Christensen SE, Seefeldt T, Helleberg K & & Pedersen KM 2007 Sources of circulating 3,5,3'-triiodothyronine in hyperthyroidism estimated after blocking of type 1 and type 2 iodothyronine deiodinases. Journal of Clinical Endocrinology and Metabolism 92 2149–2156. (https://doi.org/10.1210/jc.2007-0178)
Maia AL, Goemann IM, Meyer ELS & & Wajner SM 2011 Type 1 iodothyronine deiodinase in human physiology and disease. Journal of Endocrinology 209 283–297. (https://doi.org/10.1530/JOE-10-0481)
Mancino G, Sibilio A, Luongo C, Di Cicco E, Miro C, Cicatiello AG, Nappi A, Sagliocchi S, Ambrosio R, De Stefano MA, et al.2020 The thyroid hormone inactivator enzyme, Type 3 deiodinase, is essential for coordination of keratinocyte growth and differentiation. Thyroid 30 1066–1078. (https://doi.org/10.1089/thy.2019.0557)
Marques AR, Espadinha C, Catarino AL, Moniz S, Pereira T, Sobrinho LG & & Leite V 2002 Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. Journal of Clinical Endocrinology and Metabolism 87 3947–3952. (https://doi.org/10.1210/jcem.87.8.8756)
Mebis L, Langouche L, Visser TJ & & Van Den Berghe G 2007 The type II iodothyronine deiodinase is up-regulated in skeletal muscle during prolonged critical illness. Journal of Clinical Endocrinology and Metabolism 92 3330–3333. (https://doi.org/10.1210/jc.2007-0510)
Miro C, Ambrosio R, De Stefano MA, Di Girolamo D, Di Cicco E, Cicatiello AG, Mancino G, Porcelli T, Raia M, Del Vecchio L, et al.2017 The concerted action of Type 2 and Type 3 deiodinases regulates the cell cycle and survival of basal cell carcinoma cells. Thyroid 27 567–576. (https://doi.org/10.1089/thy.2016.0532)
Miro C, Di Cicco E, Ambrosio R, Mancino G, Di Girolamo D, Cicatiello AG, Sagliocchi S, Nappi A, De Stefano MA, Luongo C, et al.2019 Thyroid hormone induces progression and invasiveness of squamous cell carcinomas by promoting a ZEB-1/E-cadherin switch. Nature Communications 10 5410. (https://doi.org/10.1038/s41467-019-13140-2)
Miro C, Nappi A, Cicatiello AG, Di Cicco E, Sagliocchi S, Murolo M, Belli V, Troiani T, Albanese S, Amiranda S, et al.2021 Thyroid hormone enhances angiogenesis and the Warburg effect in squamous cell carcinomas. Cancers 13 2743. (https://doi.org/10.3390/cancers13112743)
Miyauchi A, Takamura Y, Ito Y, Miya A, Kobayashi K, Matsuzuka F, Amino N, Toyoda N, Nomura E & & Nishikawa M 2008 3,5,3'-triiodothyronine thyrotoxicosis due to increased conversion of administered levothyroxine in patients with massive metastatic follicular thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 93 2239–2242. (https://doi.org/10.1210/jc.2007-2282)
Moskovich D, Alfandari A, Finkelshtein Y, Weisz A, Katzav A, Kidron D, Edelstein E, Veroslavski D, Perets R, Arbib N, et al.2021 DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer. Cancer Letters 501 224–233. (https://doi.org/10.1016/j.canlet.2020.11.011)
Murakami M, Araki O, Hosoi Y, Kamiya Y, Morimura T, Ogiwara T, Mizuma H & & Mori M 2001 Expression and regulation of type II iodothyronine deiodinase in human thyroid gland. Endocrinology 142 2961–2967. (https://doi.org/10.1210/endo.142.7.8280)
Nappi A, De Stefano MA, Dentice M & & Salvatore D 2021 Deiodinases and cancer. Endocrinology 162 bqab016. (https://doi.org/10.1210/endocr/bqab016)
Nappi A, Di Cicco E, Miro C, Cicatiello AG, Sagliocchi S, Mancino G, Ambrosio R, Luongo C, Di Girolamo D, De Stefano MA, et al.2020 The NANOG transcription factor induces Type 2 deiodinase expression and regulates the intracellular activation of thyroid hormone in keratinocyte carcinomas. Cancers 12 715. (https://doi.org/10.3390/cancers12030715)
Nikiforov YE 2004 Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. Endocrine Pathology 15 319–328. (https://doi.org/10.1385/EP:15:4:319)
Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW 2ND, Tallini G, Kroll TG & & Nikiforov YE 2003 RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. Journal of Clinical Endocrinology and Metabolism 88 2318–2326. (https://doi.org/10.1210/jc.2002-021907)
Nishikawa M, Toyoda N, Yonemoto T, Ogawa Y, Tabata S, Sakaguchi N, Tokoro T, Gondou A, Yoshimura M, Yoshikawa N, et al.1998 Quantitative measurements for type 1 deiodinase messenger ribonucleic acid in human peripheral blood mononuclear cells: mechanism of the preferential increase of T3 in hyperthyroid Graves' disease. Biochemical and Biophysical Research Communications 250 642–646. (https://doi.org/10.1006/bbrc.1998.9358)
Pereira VS, Marassi MP, Rosenthal D, Vaisman M & & Correa Da Costa VM 2012 Positive correlation between type 1 and 2 iodothyronine deiodinases activities in human goiters. Endocrine 41 532–538. (https://doi.org/10.1007/s12020-011-9587-6)
Riesco-Eizaguirre G, Rodriguez I, De La Vieja A, Costamagna E, Carrasco N, Nistal M & & Santisteban P 2009 The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Research 69 8317–8325. (https://doi.org/10.1158/0008-5472.CAN-09-1248)
Romitti M, Wajner SM, Ceolin L, Ferreira CV, Ribeiro RV, Rohenkohl HC, Weber Sde S, Lopez PL, Fuziwara CS, Kimura ET, et al.2016 MAPK and SHH pathways modulate type 3 deiodinase expression in papillary thyroid carcinoma. Endocrine-Related Cancer 23 135–146. (https://doi.org/10.1530/ERC-15-0162)
Romitti M, Wajner SM, Zennig N, Goemann IM, Bueno AL, Meyer ELS & & Maia AL 2012 Increased type 3 deiodinase expression in papillary thyroid carcinoma. Thyroid 22 897–904. (https://doi.org/10.1089/thy.2012.0031)
Russo D, Bulotta S, Bruno R, Arturi F, Giannasio P, Derwahl M, Bidart J, Schlumberger M & & Filetti S 2001 Sodium/iodide symporter (NIS) and pendrin are expressed differently in hot and cold nodules of thyroid toxic multinodular goiter. European Journal of Endocrinology 145 591–597. (https://doi.org/10.1530/eje.0.1450591)
Salvatore D, Porcelli T, Ettleson MD & & Bianco AC 2022 The relevance of T3 in the management of hypothyroidism. Lancet Diabetes and Endocrinology 10 366–372. (https://doi.org/10.1016/S2213-8587(2200004-3)
Salvatore D, Tu H, Harney JW & & Larsen PR 1996 Type 2 iodothyronine deiodinase is highly expressed in human thyroid. Journal of Clinical Investigation 98 962–968. (https://doi.org/10.1172/JCI118880)
Saqcena M, Leandro-Garcia LJ, Maag JLV, Tchekmedyian V, Krishnamoorthy GP, Tamarapu PP, Tiedje V, Reuter V, Knauf JA, De Stanchina E, et al. 2021. SWI/SNF Complex Mutations Promote Thyroid Tumor Progression and Insensitivity to Redifferentiation Therapies. Cancer Discovery 11 1158–1175. (https://doi.org/10.1158/2159-8290.CD-20-0735)
Schreck R, Schnieders F, Schmutzler C & & Kohrle J 1994 Retinoids stimulate type I iodothyronine 5'-deiodinase activity in human follicular thyroid carcinoma cell lines. Journal of Clinical Endocrinology and Metabolism 79 791–798. (https://doi.org/10.1210/jcem.79.3.8077363)
Silva JE & & Larsen PR 1983 Adrenergic activation of triiodothyronine production in brown adipose tissue. Nature 305 712–713. (https://doi.org/10.1038/305712a0)
Simonides WS, Mulcahey MA, Redout EM, Muller A, Zuidwijk MJ, Visser TJ, Wassen FW, Crescenzi A, da-Silva WS, Harney J, et al.2008 Hypoxia-inducible factor induces local thyroid hormone inactivation during hypoxic-ischemic disease in rats. Journal of Clinical Investigation 118 975–983. (https://doi.org/10.1172/JCI32824)
Takano T, Miyauchi A, Ito Y & & Amino N 2006 Thyroxine to triiodothyronine hyperconversion thyrotoxicosis in patients with large metastases of follicular thyroid carcinoma. Thyroid 16 615–618. (https://doi.org/10.1089/thy.2006.16.615)
Toyoda N, Zavacki AM, Maia AL, Harney JW & & Larsen PR 1995 A novel retinoid X receptor-independent thyroid hormone response element is present in the human type 1 deiodinase gene. Molecular and Cellular Biology 15 5100–5112. (https://doi.org/10.1128/MCB.15.9.5100)
